FI946083A - Antianginaaliset purinonit - Google Patents

Antianginaaliset purinonit Download PDF

Info

Publication number
FI946083A
FI946083A FI946083A FI946083A FI946083A FI 946083 A FI946083 A FI 946083A FI 946083 A FI946083 A FI 946083A FI 946083 A FI946083 A FI 946083A FI 946083 A FI946083 A FI 946083A
Authority
FI
Finland
Prior art keywords
alkyl
purinones
antianginal
so2nr
pyrrolidino
Prior art date
Application number
FI946083A
Other languages
English (en)
Swedish (sv)
Other versions
FI946083A0 (fi
Inventor
Nicholas Kenneth Terrett
Original Assignee
Pfizer Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Res & Dev filed Critical Pfizer Res & Dev
Publication of FI946083A0 publication Critical patent/FI946083A0/fi
Publication of FI946083A publication Critical patent/FI946083A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine
FI946083A 1992-06-26 1994-12-23 Antianginaaliset purinonit FI946083A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB929213623A GB9213623D0 (en) 1992-06-26 1992-06-26 Therapeutic agents
PCT/EP1993/001561 WO1994000453A1 (en) 1992-06-26 1993-06-18 Purinone antianginal agents

Publications (2)

Publication Number Publication Date
FI946083A0 FI946083A0 (fi) 1994-12-23
FI946083A true FI946083A (fi) 1994-12-23

Family

ID=10717795

Family Applications (1)

Application Number Title Priority Date Filing Date
FI946083A FI946083A (fi) 1992-06-26 1994-12-23 Antianginaaliset purinonit

Country Status (11)

Country Link
EP (1) EP0647227B1 (fi)
JP (1) JP2544903B2 (fi)
AT (1) ATE143961T1 (fi)
CA (1) CA2139109C (fi)
DE (1) DE69305344T2 (fi)
DK (1) DK0647227T3 (fi)
ES (1) ES2092316T3 (fi)
FI (1) FI946083A (fi)
GB (1) GB9213623D0 (fi)
GR (1) GR3021878T3 (fi)
WO (1) WO1994000453A1 (fi)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI951367A (fi) * 1994-03-28 1995-09-29 Japan Energy Corp Puriinijohdannaiset ja tulehdustautien tukahduttajat (suppressantit)
GB9423911D0 (en) * 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
GB9423910D0 (en) 1994-11-26 1995-01-11 Pfizer Ltd Therapeutic agents
DE19501482A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 2,9-disubstituierte Purin-6-one
DE19501480A1 (de) * 1995-01-19 1996-07-25 Bayer Ag 9-substituierte 2-(2-n-Alkoxyphenyl)-purin-6-one
US5656629A (en) * 1995-03-10 1997-08-12 Sanofi Winthrop, Inc. 6-substituted pyrazolo (3,4-d)pyrimidin-4-ones and compositions and methods of use thereof
JPH1087666A (ja) * 1996-09-18 1998-04-07 Kyorin Pharmaceut Co Ltd デュオカルマイシンｓａ及びその誘導体の製造中間体と製造方法
DE19702785A1 (de) * 1997-01-27 1998-07-30 Bayer Ag Neue cyclische Harnstoffderivate
EA002057B1 (ru) 1997-04-25 2001-12-24 Пфайзер Инк. ПИРАЗОЛОПИРИМИДИНОНЫ, КОТОРЫЕ ИНГИБИРУЮТ ЦИКЛИЧЕСКИЙ ГУАНОЗИН-3',5'-МОНОФОСФАТ-ФОСФОДИЭСТЕРАЗУ ТИПА 5 (cGMP PDE5), ДЛЯ ЛЕЧЕНИЯ СЕКСУАЛЬНОГО РАССТРОЙСТВА
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
DE19881732D2 (de) 1997-11-12 2000-08-24 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone als Phoshodiesterase Inhibitoren
SK15532000A3 (sk) 1998-04-20 2001-12-03 Pfizer Inc. Pyrazolopyrimidínové inhibítory cgmp pde5 na použitie na liečbu sexuálnych dysfunkcií, spôsob ich prípravy, medziprodukty a farmaceutický prostriedok s ich obsahom
WO1999062905A1 (en) * 1998-06-03 1999-12-09 Almirall Prodesfarma, S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
US6087368A (en) * 1998-06-08 2000-07-11 Bristol-Myers Squibb Company Quinazolinone inhibitors of cGMP phosphodiesterase
DE19838300A1 (de) * 1998-08-24 2000-03-02 Bayer Ag 9-Dialkylaminopurinon-derivate
US6326379B1 (en) * 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
GB9823102D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823101D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
GB9823103D0 (en) 1998-10-23 1998-12-16 Pfizer Ltd Pharmaceutically active compounds
US6225315B1 (en) 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance
CN1378547A (zh) 1999-10-11 2002-11-06 辉瑞大药厂 用作磷酸二酯酶抑制剂的5－(2－取代的－5－杂环基磺酰基吡啶－3－基)－二氢吡唑并[4,3－d]嘧啶－7－酮类化合物
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
GB9924020D0 (en) * 1999-10-11 1999-12-15 Pfizer Ltd Pharmaceutically active compounds
US6683081B2 (en) 1999-12-24 2004-01-27 Bayer Aktiengesellschaft Triazolotriazinones and the use thereof
EP1365806A2 (en) * 2000-04-19 2003-12-03 Johns Hopkins University Use of no acttivators for treatment and prevention of gastrointestinal disorders
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
ES2337887T3 (es) 2001-12-20 2010-04-30 Merck Serono Sa Derivados de pirrolidina en calidad de moduladores de prostaglandina.
GB0202282D0 (en) 2002-01-31 2002-03-20 Pfizer Ltd Treatment of male sexual dysfunction
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
NZ567457A (en) 2002-12-13 2009-08-28 Warner Lambert Co Alpha-2-delta ligand to treat lower urinary tract symptoms
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
DK1742950T3 (da) 2004-04-07 2009-03-16 Pfizer Ltd Pyrazolo-[4,3-D]-pyrimidiner
WO2006100557A1 (en) 2005-03-21 2006-09-28 Pfizer Limited Substituted triazole derivatives as oxytocin antagonists
ATE493413T1 (de) 2005-05-12 2011-01-15 Pfizer Wasserfreie kristalline formen von n-ä1,2- ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4- methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-
WO2013067309A1 (en) 2011-11-04 2013-05-10 Xion Pharmaceutical Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
EP0347146B1 (en) * 1988-06-16 1993-09-01 Smith Kline & French Laboratories Limited Fused pyrimidine derivatives, process and intermediates for their preparation and pharmaceutical compositions containing them
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds

Also Published As

Publication number Publication date
JP2544903B2 (ja) 1996-10-16
CA2139109C (en) 1997-03-25
JPH07504681A (ja) 1995-05-25
FI946083A0 (fi) 1994-12-23
GR3021878T3 (en) 1997-03-31
EP0647227A1 (en) 1995-04-12
DK0647227T3 (da) 1996-11-18
GB9213623D0 (en) 1992-08-12
ATE143961T1 (de) 1996-10-15
DE69305344D1 (de) 1996-11-14
WO1994000453A1 (en) 1994-01-06
CA2139109A1 (en) 1994-01-06
ES2092316T3 (es) 1996-11-16
EP0647227B1 (en) 1996-10-09
DE69305344T2 (de) 1997-02-20

Similar Documents

Publication Publication Date Title
FI946083A (fi) Antianginaaliset purinonit
FI942769A0 (fi) Antianginaaliset kinatsolinonit
EP0656898A1 (en) PYRIDOPYRIMIDINONE ANTIANGINOUS AGENTS.
YU108791A (sh) Pirazolopirimidinon antianginalna jedinjenja
BR1100029A (pt) Agentes antiangìnicos de pirazolpirimidinonas
IL116122A0 (en) Intermediates to heterocyclic-cyclic amine derivatives
NO934792L (no) Xantinderivater

Legal Events

Date Code Title Description
FD Application lapsed